Next-Gen Diagnostics for Stroke & Alzheimer’s Risk
Next-Gen Diagnostics for Stroke & Alzheimer’s Risk
Project profile curated by GlobalReach Link. Applications are reviewed on a rolling basis.
Project Overview
A health-tech startup building a low-cost, non-invasive diagnostic tool to detect biomarkers linked to stroke and Alzheimer’s disease risk through saliva. The platform also incubates next-gen medical researchers, enabling innovation in cerebrovascular and neurodegenerative disease diagnostics. The tool is enhanced by AI analytics and aims to deliver mass-market screening, even in resource-constrained settings.
Project Goals
Skills Needed
Competitive Advantage
– First-in-market saliva-based detection with AI analytics
– Combines diagnostics and medtech incubation for portfolio diversification
– Led by neuroscience PhD and internationally awarded researcher
– Supported by decades of multi-country bio-sample data
– Focused on affordability and mass access in both developed and emerging health systems
Reasons to Invest & Market Opportunity
– Targets a global diagnostics market valued over USD 70B
– AI-powered platform with biomarker testing via saliva strip
– Strong founder-led mission backed by 20+ years of scientific data
– Expected 5x ROI over 5 years (projected)
– Combines commercial diagnostics and health innovation incubation
– Social impact focus with early detection for underserved populations
– Global stroke cases and Alzheimer’s patients rising steeply (55M now to 139M by 2050)
– No scalable early detection method for most of the world
– Platform plays at the intersection of diagnostics (USD 70B+) and digital health innovation
– High impact in Asia-Pacific, MENA, and global aging populations
Problem & Solution
Problem: Stroke is the 2nd leading cause of global mortality. Current diagnostics are either costly, invasive, or reactive. Alzheimer’s remains undetected until late-stage symptoms appear.
Solution: This platform uses AI to analyze non-invasive enzyme signals from saliva—delivering affordable, scalable screening at the pre-symptomatic stage. It also trains and funds medical innovators to fast-track new neurodiagnostic solutions to market.
Highlights
– Prototype wearable “Stroke Meter” under pilot testing
– Incubation program launched to fund next-gen cerebrovascular healthtech
– Saliva test strip using electronic ink offers needle-free early risk analysis
– Enzyme-linked biomarker showing predictive value confirmed in pre-pilot cohorts
– Strong interest from UAE, South Asia, and Australia-based collaborators
Exit Strategy
Apply to Join
Applications are reviewed by the GlobalReach coordination team. Only shortlisted experts will be contacted (NDA for documents).
Sign in may be required before submission.
